Suppr超能文献

IgG4相关性肾病糖皮质激素治疗后肾皮质萎缩发生的相关因素:一项回顾性多中心研究

Factors related to renal cortical atrophy development after glucocorticoid therapy in IgG4-related kidney disease: a retrospective multicenter study.

作者信息

Mizushima Ichiro, Yamamoto Motohisa, Inoue Dai, Nishi Shinichi, Taniguchi Yoshinori, Ubara Yoshifumi, Matsui Shoko, Yasuno Tetsuhiko, Nakashima Hitoshi, Takahashi Hiroki, Yamada Kazunori, Nomura Hideki, Yamagishi Masakazu, Saito Takao, Kawano Mitsuhiro

机构信息

Division of Rheumatology, Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, Takara-machi 13-1, Kanazawa, Ishikawa, 920-8640, Japan.

Division of Nephrology and Rheumatology, Department of Internal Medicine, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.

出版信息

Arthritis Res Ther. 2016 Nov 25;18(1):273. doi: 10.1186/s13075-016-1175-y.

Abstract

BACKGROUND

In immunoglobulin G4-related kidney disease (IgG4-RKD), focal or diffuse renal cortical atrophy is often observed in the clinical course after glucocorticoid therapy. This study aimed to clarify the factors related to renal atrophy after glucocorticoid therapy in IgG4-RKD.

METHODS

We retrospectively evaluated clinical features including laboratory data and computed tomography (CT) findings before and after glucocorticoid therapy in 23 patients diagnosed with IgG4-RKD, all of whom were followed up for more than 24 months.

RESULTS

Seventeen patients were men, and six were women (average age 62.0 years). Average follow-up period was 54.9 months. The average estimated glomerular filtration rate (eGFR) at diagnosis was 81.7 mL/min/1.73 m. All patients had had multiple low-density lesions on contrast-enhanced CT before glucocorticoid therapy, and showed disappearance or reduction of these lesions after it. Pre-treatment eGFR and serum IgE level in 11 patients in whom renal cortical atrophy developed 24 months after the start of glucocorticoid therapy were significantly different from those in 12 patients in whom no obvious atrophy was found at that time (68.9 ± 30.1 vs 93.5 ± 14.1 mL/min/1.73 m, P = 0.036, and 587 ± 254 vs 284 ± 263 IU/mL, P = 0.008, respectively). Pre-treatment eGFR and serum IgE level were also significant risk factors for renal atrophy development 24 months after the start of therapy with an odds ratio of 0.520 (per 10 mL/min/1.73 m, 95% confidence interval (CI) 0.273-0.993, P = 0.048) and 1.090 (per 10 IU/mL, 95% CI: 1.013-1.174, P = 0.022), respectively, in age-adjusted, sex-adjusted, serum IgG4 level-adjusted logistic regression analysis. Receiver operating characteristic curve analysis showed that eGFR of less than 71.0 mL/min/1.73 m and serum IgE of more than 436.5 IU/mL were the most appropriate cutoffs and yielded sensitivity of 63.6% and specificity of 100%, and sensitivity of 90.9% and specificity of 75.0%, respectively, in predicting renal atrophy development.

CONCLUSIONS

This study suggests that pre-treatment renal insufficiency and serum IgE elevation predict renal atrophy development after glucocorticoid therapy in IgG4-RKD.

摘要

背景

在免疫球蛋白G4相关性肾病(IgG4-RKD)中,糖皮质激素治疗后的临床病程中常观察到局灶性或弥漫性肾皮质萎缩。本研究旨在阐明IgG4-RKD患者糖皮质激素治疗后肾萎缩的相关因素。

方法

我们回顾性评估了23例诊断为IgG4-RKD患者的临床特征,包括糖皮质激素治疗前后的实验室数据和计算机断层扫描(CT)结果,所有患者均接受了超过24个月的随访。

结果

17例为男性,6例为女性(平均年龄62.0岁)。平均随访期为54.9个月。诊断时平均估计肾小球滤过率(eGFR)为81.7 mL/min/1.73m²。所有患者在糖皮质激素治疗前对比增强CT上均有多个低密度病变,治疗后这些病变消失或缩小。糖皮质激素治疗开始24个月后发生肾皮质萎缩的11例患者与当时未发现明显萎缩的12例患者相比,治疗前eGFR和血清IgE水平有显著差异(分别为68.9±30.1 vs 93.5±14.1 mL/min/1.73m²,P = 0.036;587±254 vs 284±263 IU/mL,P = 0.008)。在年龄、性别、血清IgG4水平校正的逻辑回归分析中,治疗前eGFR和血清IgE水平也是治疗开始24个月后肾萎缩发生的显著危险因素,优势比分别为0.520(每10 mL/min/1.73m²,95%置信区间(CI)0.273 - 0.993,P = 0.048)和1.090(每10 IU/mL,95%CI:1.013 - 1.174,P = 0.022)。受试者工作特征曲线分析显示,eGFR低于71.0 mL/min/1.73m²和血清IgE高于436.5 IU/mL是预测肾萎缩发生的最合适切点,预测肾萎缩发生的敏感性分别为63.6%和特异性为100%,以及敏感性为90.9%和特异性为75.0%。

结论

本研究表明,治疗前肾功能不全和血清IgE升高可预测IgG4-RKD患者糖皮质激素治疗后肾萎缩的发生。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c607/5123425/f826d2175c6e/13075_2016_1175_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验